New Conjugates of Hyaluronic Acid with γ-Cyclodextrin as Sorafenib Carrier in Cancer Cells.
ChemMedChem
; : e202400219, 2024 Jun 10.
Article
en En
| MEDLINE
| ID: mdl-38856008
ABSTRACT
In recent years, nanoparticles based on cyclodextrins have been widely investigated, mainly for drug delivery. In this work, we synthesized nanoparticles with a hyaluronic acid backbone (11â
kDa and 45â
kDa) functionalized with γ-cyclodextrins. We tested sorafenib in the presence of the new hyaluronan-cyclodextrin conjugates in A2780 (ovarian cancer), SK-HeP-1 (adenocarcinoma) and MDA-MB-453 (breast cancer) cell lines. We found that hyaluronan-cyclodextrin conjugates improve the antiproliferative activity of sorafenib. Remarkably, the system based on the 11â
kDa hyaluronan conjugate was the most effective and, in the MDA-MB-453â
cell line, significantly reduced the IC50 value of sorafenib cells by about 75 %.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
ChemMedChem
Asunto de la revista:
FARMACOLOGIA
/
QUIMICA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Italia